VRTX - Vertex Pharmaceuticals Incorporated
| Previous Close | 156.97 |
| Open | 157.00 |
| Bid | 157.25 x 1200 |
| Ask | 157.27 x 1000 |
| Day's Range | 156.22 - 157.90 |
| 52 Week Range | 118.05 - 178.15 |
| Volume | 449,118 |
| Avg. Volume | 1,495,036 |
| Market Cap | 40.108B |
| Beta | 1.94 |
| PE Ratio (TTM) | 151.48 |
| EPS (TTM) | 1.04 |
| Earnings Date | Jul 24, 2018 - Jul 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 192.00 |
- InvestorPlace•3 days ago
The 10 Fastest-Growing Stocks to Invest In Right Now
The company is the name behind a large collection of 3D modeling and computer-aided drafting platforms — most of which are sold on a subscription basis. Who know cloud-based drafting software could help create one of the market’s top fast-growing stocks?
Market Realist•3 days agoTesaro Stock: What’s the Upside Potential?
Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.
Market Realist•3 days agoGauging the Upside Potential of Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.
Market Realist•3 days agoVertex Pharmaceuticals: Drugs That Are Making It Happen
Vertex Pharmaceuticals’ (VRTX) Kalydeco generated sales of $249.5 million in the first quarter, up from $185.7 million YoY (year-over-year). The drug is targeted to treat cystic fibrosis patients with G551D mutation in the CFTR gene. The increase was due to additional patients being treated with Kalydeco after Vertex completed reimbursement discussions in non-US jurisdictions and due to an increase in the number of eligible patients to receive Kalydeco through label expansion.
- Market Realist•3 days ago
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18. On May 18, the stock closed at $3.46, a 119% increase from its 52-week low of $1.58 on May 19, 2017. On May 15, 2018, MEI Pharma stock closed at $3.40, a ~34.4% increase over the previous close of $2.53 on May 14, 2018. The stock rose ~58% in the last quarter.
- Market Realist•7 days ago
Why Wall Street Analysts Are Mostly Positive on CRISPR
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
- Zacks•9 days ago
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
- Investopedia•9 days ago
CRISPR Stocks Deserve a Second Look. Here's Why.
Clustered Regularly Interspaced Short Palindromic Repeats, commonly known as CRISPR, the revolutionary gene editing method was first discovered by Francisco Monica in Spain, as a means to defend one’s body from invading viruses. To start with, let’s first focus on what exactly the gene editing process entails. Gene editing is primarily inserting, deleting or replacing DNA base pairs within a gene.
Market Realist•15 days agoHow Did Jazz Pharmaceuticals Perform in 1Q18?
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.
- GlobeNewswire•15 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial — New Research Emphasizes Economic Growth
NEW YORK, May 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American ...
Markit•16 days agoSee what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX
- Motley Fool•16 days ago
3 Top Biotech Stocks to Buy in May
Looking for a few timely buys in the biotech space? Give these gems a closer look.
- InvestorPlace•17 days ago
7 Fast-Growing Stocks to Buy Today
Editor’s Note: This is a replay of a story that originally ran March 2, 2018. It has since been updated and republished.
- Motley Fool•17 days ago
Here's My Top Stock to Buy in May
A near monopoly and multiple paths for growth make this my favorite stock to buy right now.
- Market Realist•18 days ago
Wall Street Recommendations for Exelixis in May 2018
As per the terms of the agreement, Exelixis and Invenra will jointly discover and develop antibodies with the help of Invenra’s B-Body technology platform, which allows high-throughput screening along with in vitro and in vivo preclinical characterization for the development of potential therapeutic candidates. According to the terms of the agreement, Exelixis will lead preclinical trials, manufacturing, the clinical development of both single-regimen and combination-regimen therapies along with regulatory filling and commercialization. Also under this collaboration, Exelixis and Invenra plan to conduct up to six discovery projects.
Market Realist•21 days agoHow Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million yesterday, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
- Zacks•23 days ago
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
- Business Wire•24 days ago
Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members
Vertex Pharmaceuticals Incorporated (VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program. Each of the 80 scholarship recipients will be awarded $5,000 for the 2018-2019 academic year. The Vertex All in for CF Scholarship program was established in 2017 to help people living with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees.
- ACCESSWIRE•24 days ago
Blog Exposure - EMA Scientific Committee Recommended Granting Marketing Authorization to Gilead's Biktarvy(R) for HIV-1 Treatment
LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GILD as the Company's latest news hit the wire.
- Bloomberg•24 days ago
Medicaid Is Right to Demand Lower Drug Prices
Last week, as President Donald Trump delayed announcing his plan to bring down high drug prices, about a dozen physicians, pharmacists, actuaries and economists in Albany, New York, tried to make a difference. The state Medicaid program's Drug Utilization Review Board voted 10-0 to lower the price New York would pay for Orkambi, Vertex Pharmaceuticals' cystic fibrosis drug, to $83,000 per year, from $250,000. As a lung physician, I appreciate that Orkambi does have benefits — it eases breathing and prevents some of the acute episodes that can land cystic fibrosis patients in the hospital.
- Motley Fool•25 days ago
Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock
The news shouldn't distract from a solid first quarter.
- Investopedia•25 days ago
Google's Alphabet Median Pay Close To $200K
Alphabet Inc. ( GOOG), Google's parent company, paid its employees nearly $200,000 last year, placing it in fourth place in terms of median compensation among S&P 500 Index companies that disclose pay. Citing Alphabet, the Wall Street Journal reported that in 2017 it had median pay packages of more than $197,000, which was 18% below Facebook Inc. ( FB) where the median salary was $240,000 in 2017. Excluding the two, which are embroiled in a talent war with other technology companies, the median salary for companies in the S&P 500 was $69,205, noted the Wall Street Journal.
- Thomson Reuters StreetEvents•26 days ago
Edited Transcript of VRTX earnings conference call or presentation 26-Apr-18 8:30pm GMT
Q1 2018 Vertex Pharmaceuticals Inc Earnings Call
Yahoo Finance Video•18 days agoMARKETS: Here's why stellar earnings aren't boosting stocks higher
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance Video•25 days agoMARKETS: Oil markets react to Iran latest, Apple stocks up ahead of earnings report, Walmart helps retails sector
Latest market news with Yahoo Finance's Seana Smith and Jared Blikre.
